One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases.

Van Voorhis, Wesley C; Hulverson, Matthew A; Choi, Ryan; Huang, Wenlin; Arnold, Samuel L M; Schaefer, Deborah A; Betzer, Dana P; Vidadala, Rama S R; Lee, Sangun; Whitman, Grant R; Barrett, Lynn K; Maly, Dustin J; Riggs, Michael W; Fan, Erkang; Kennedy, Thomas J; Tzipori, Saul; Doggett, J Stone; Winzer, Pablo; Anghel, Nicoleta; Imhof, Dennis; ... (2021). One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases. Veterinary parasitology, 289, p. 109336. Elsevier 10.1016/j.vetpar.2020.109336

Text 1-s2.0-S0304401720303162-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (2MB) | Request a copy

This is a review of the development of bumped-kinase inhibitors (BKIs) for the therapy of One Health parasitic apicomplexan diseases. Many apicomplexan infections are shared between humans and livestock, such as cryptosporidiosis and toxoplasmosis, as well as livestock only diseases such as neosporosis. We have demonstrated proof-of-concept for BKI therapy in livestock models of cryptosporidiosis (newborn calves infected with Cryptosporidium parvum), toxoplasmosis (pregnant sheep infected with Toxoplasma gondii), and neosporosis (pregnant sheep infected with Neospora caninum). We discuss the potential uses of BKIs for the treatment of diseases caused by apicomplexan parasites in animals and humans, and the improvements that need to be made to further develop BKIs.

Interest & Impact

Downloads

1 since deposited on 17 Feb 2021
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item